mc2-CMX
The mc2-CMX vaccine is a live attenuated vaccine that was developed using M. tuberculosis Ag85, MPT-51 and HSP-x to generate a fusion protein called CMX. The nucleotide sequences corresponding to epitopes 85 to 159 bp of Ag85C and 91 to 112 bp of MPT51 and HSP-x. The gene sequence was inserted in the genome of…
Read MoreREA
A multifusion protein-based vaccine formulated with MPL/DDA.
Read MoreNETB-EA
The Khader Lab in collaboration with EclipTB Inc andBlueWillow Biologics Inc., have developed an intranasal booster sub-unit, mucosal vaccine comprising of Mtb immunodominant antigens Early secreted antigenic target 6 kDa andAntigen 85B together with nanoemulsion adjuvant NE01-NETB-EA.
Read MoreAd5-105K
The Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) developed by CanSino Biologics Inc. is a non-replicating viral-vectored vaccine intended for administration via nebulized inhalation by mouth. It is designed to induce both local mucosal immunity in the respiratory tract and systemic immune responses against Mycobacterium tuberculosis (Mtb). The adenovirus type 5 (Ad5) backbone functions as…
Read MoreBCG-STING
BCG-STING is a recombinant BCG strain that overexpresses the small molecule STING agonist cyclic di-AMP. For prevention of Mtb proliferation BCG-STING is more potent than standard BCG in mouse, guinea pig, and NHP models, and it is also safer than BCG-WT in mouse models. BCG-STING can be produced by fermentation, overcoming current BCG production limitations.
Read More